on MEDINCELL (EPA:MEDCL)
Medincell Announces Video Conference for Half-Year Results
Medincell, a French biopharmaceutical company listed on Euronext, will hold a video conference on December 10, 2024 to unveil its half-year financial results covering the period from April to September 2024. The sessions are scheduled for 6:00 p.m. in French and 7:00 p.m. in English.
Shareholders will be able to interact by sending questions in advance via email or via a messaging module during the conference. This virtual meeting aims to update stakeholders on the company's recent performance.
Medincell is developing extended-release injectable drugs using its proprietary BEPO® technology. The first treatment, UZEDY®, for schizophrenia, is currently marketed in the United States by Teva.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDINCELL news